Daxor Corporation shares fall 8.83% after-hours despite FDA clearance for new Blood Volume Analyzer.

Daxor Corporation dropped 8.83% in after-hours trading, despite receiving FDA clearance for its next-generation Blood Volume Analyzer (BVA) device. The new device quantifies a patient's blood volume against patient-specific norms, enabling precise fluid management across a broad spectrum of clinical conditions.